Alembic Pharmaceuticals Ltd - 533573 - Loss of Share Certificate / Issue of Duplicate Share Certificate
Alembic Pharmaceuticals Ltd has informed BSE regarding Loss of Share Certificate / Issue of Duplicate Share Certificate.25-12-2018
25-12-2018
Broker's call: Alembic Pharma (Sell)
EquirusAlembic Pharma (Sell)CMP: 596.8Target: 514Alembic Pharmaceuticals is engaged developing formulations and active pharmaceutical ingredients (19-12-2018
Alembic Pharmaceuticals Ltd - 533573 - Successful US FDA Inspection At Alembic Pharmaceuticals Limited API Facility At Panelav
We would like to inform that the United States Food and Drug Administration (US FDA) has conducted an inspection at Alembic Pharmaceuticals Limited API Facility located at Panelav from 17th December, 2018 to 19th December, 2018. This was a scheduled inspection and at the end of the inspection, there were zero 483s. We request you to kindly take the same on record.19-12-2018
Alembic Pharma raises 350 cr via NCDs
Drug firm Alembic Pharmaceuticals on Friday said it has raised 350 crore through allotment of non-convertible debentures (NCDs) on private placement14-12-2018
Announcement under Regulation 30 (LODR)-Allotment
With reference to the captioned matter, the exchange is hereby informed that the NCD Committee of Alembic Pharmaceuticals Limited at its meeting held today has inert-alia allotted: 1. 1,500 (One Thousand Five Hundred) 9% Rated Unsecured Listed Redeemable Non-Convertible Debentures ('NCDs') of Rs. 10,00,000/- (Rs. Ten Lacs) per NCD aggregating to Rs. 150,00,00,000/- (Rs. One Hundred and Fifty Crores) under Tranche I; and...14-12-2018
Alembic Pharma gets USFDA nod for ophthalmic solution
Alembic Pharmaceuticals has received approval from the US health regulator for Olopatadine Hydrochloride ophthalmic solution, used to treat allergic c10-12-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1%. Please find enclosed herewith our press release. We request you to kindly take the same on record.10-12-2018
Announcement under Regulation 30 (LODR)-Issue of Securities
With reference to the captioned matter, the exchange is hereby informed that a Meeting of the NCD Committee of the Company will be held on Friday, 14th December, 2018, inter-alia to consider and approve the issue and allotment of Unsecured Listed Redeemable Non-Convertible Debentures (NCDs) of upto Rs. 350 Crores on Private Placement Basis. We request you to kindly take the same on record.07-12-2018
Company news: Alembic Pharmaceuticals
Drug firm Alembic Pharmaceuticals on Thursday said it plans to raise up to 500 crore through issue of non-convertible debentures (NCDs) on private pl07-12-2018
Outcome of Board Meeting
With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter-alia (i) approved the Issue of Unsecured Listed Redeemable Non-Convertible Debentures (NCDs) of upto Rs. 500 Crores on Private Placement Basis under a shelf disclosure document in multiple tranches and (ii) Constituted NCD Committee for issue and allotment of NCDs....06-12-2018